Pharmaceutical Technology on MSN

Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar

Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second quarter of 2026.
Slate

Will the Autobahn Finally Get Speed Limits?

The round sign is iconic, printed on T-shirts and keychains. A black circle rings the perimeter, with five black lines slicing diagonally from bottom left to top right. To spot this sign in the wild, ...
BioWorld

Autobahn on the fast track with bipolar thyroid agonist

Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous system thyroid hormone receptor ...
Pharmabiz

Autobahn Therapeutics receives US FDA fast track designation for Elunetirom for adjunctive treatment of bipolar depression

Autobahn Therapeutics Inc, a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, announced that the US Food and Drug Administration granted fast ...
NPR

Germany might ask drivers to pump the brakes on the Autobahn

The country is considering putting speed limits on its highway network — and the move is leading to some soul searching. Germany is known for many things - beer, World War II, cars - which brings us ...
Rutland Herald

Autobahn Therapeutics Announces U.S. FDA Fast Track Designation for Elunetirom, a CNS-Directed Thyroid Hormone Receptor Agonist, for the Adjunctive Treatment of Bipolar Depression

Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration ...